期刊文献+

大鼠眼玻璃体腔注射人脐带间充质干细胞后致眼内感染的实验研究

Experimental study of endophthalmitis resulted from rat intravitreal injection of human umbilical cord mesenchymal stem cells
原文传递
导出
摘要 目的比较不同方式玻璃体腔注射人脐带间充质干细胞(hUC-MSCs)后眼内感染率,为寻找减少眼内感染的注射方式。方法采用酶消化法进行人脐带间充质干细胞提取,流式细胞仪检测其表面标志CD73、CD105、Anti-HLA-ABC、CD34、CD45、Anti-HLA-DR;将60只SD大鼠120只眼随机分为上方玻璃体腔注射组和下方玻璃体腔注射组,各60只眼;对感染眼内炎的大鼠抽取玻璃体,进行细菌培养检测。结果 120只大鼠眼中5眼出现感染性眼内炎,总感染率为4.2%,其中4只眼为下方注射组,1只眼为上方注射组,两组的感染率分别为6.7%及1.7%,两组比较差异有统计学意义(P<0.05);感染病原菌为金黄色葡萄球菌2株、表皮葡萄球菌2株、链球菌属1株。结论选择上方玻璃体腔注射是比较安全的方式,可能会减少眼内感染的发病率。 OBJECTIVE To compare incidences of endophthalmitis with different methods of intravitreal injection of human umbilical cord mesenchymal stem cells and to explore a more secure injection way to reduce endophthalmitis.METHODS Enzyme digestion method was used to extract hUC-MSCs,flow cytometry was used to detect surface marks including CD73,CD105,anti-HLA ABC,CD34,CD45,anti-HLA-DR.Totally 60 healthy SD rats(120eyes)were randomly divided into superior injection group and inferior injection group.Vitreous humors were extracted from rats infected with endophthalmitis and were used for bacterial culture detection.RESULTS A total of five eyes developed infectious endophthalmitis and total infection rate was 4.2%.Among them,four eyes were injected inferiorly and one eye was injected superiorly.The infection rates respectively were 6.7% and 1.7%.Between two groups,there was statistically difference(P〈0.05).Bacterial culture results showed that there were 2cases of Staphylococcus aureus,2cases of Staphylococcus epidermis,and 1case of Streptococcus.CONCLUSION Superior intravitreal injections is a relatively safe way and may reduce the rate of endophthalmitis.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2016年第8期1831-1833,共3页 Chinese Journal of Nosocomiology
基金 国家自然科学基金资助项目(81301647) 山东省科技厅优秀中青年科学家科研奖励基金资助项目(2012BSB14014)
关键词 人脐带间充质干细胞 眼内炎 玻璃体腔注射 Human umbilical cord mesenchymal stem cells Endophthalmitis Intravitreal injection
  • 相关文献

参考文献6

  • 1Fagan XJ,Al-Qureshi S.Intravitreal injections:a review of the evidence for best practice:response[J].Clin Experiment Ophthalmol,2014,42(1):98-100.
  • 2Mason JO,White MF,Feist RM,et al.Incidence of acute onset endophthalmitis following intravitreal bevacizumab(Avastin)injection[J].Retina,2008,28(4):564-567.
  • 3Sampat KM,Garg SJ.Complications of intravitreal injections[J].Curr Opin Ophthalmol,2010,21(3):178-183.
  • 4Bhavsar AR,Googe JM Jr,Stockdale CR,et al.Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required:the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials[J].Arch Ophthalmol,2009,127(12):1581-1583.
  • 5李逸丰,魏文斌.玻璃体内注药术后眼内炎的危险因素及预防[J].国际眼科纵览,2013,37(5):345-349. 被引量:2
  • 6Englander M,Chen TC,Paschalis EI,et al.Intravitreal injections at the Massachusetts Eye and Ear Infirmary:analysis of treatment indications and postinjection endophthalmitis rates[J].Br J Ophthalmol,2013,97(4):460-465.

二级参考文献29

  • 1Fagan XJ, Al-Qureshi S. Intravitreal injections : a review of theevidence for best practice. Clin Experiment Ophthalmol, 2013 ,41: 500-507.
  • 2Jager RD, Aiello LP, Patel SC, et al. Risks of intravitreous injec-tion: a comprehensive review. Retina, 2004, 24 : 676-698.
  • 3Shea AM,Curtis LH,Hammill BG,et al. Resource use and costsassociated with diabetic macular edema in elderly patients. ArchOphthalmol, 2008,126: 1748-1754.
  • 4Day S,Acquah K, Mruthyunjaya P, et al. Ocular complicationsafter anti-vascular endothelial growth factor therapy in medicare pa-tients with age-related macular degeneration. Am J Ophthalmol,2011,152: 266-272.
  • 5Mason JO III, White MF, Feist RM, et al. Incidence of acute on-set endophthalmitis following intravitreal Bevacizumab ( Avastin)injection. Retina, 2008,28: 564-567.
  • 6Bhavsar AR, Googe JM Jr, Stockdale CH, et al. Risk of endoph-thalmitis after intravitreal drug injection when topical antibioticsare not required : the diabetic retinopathy clinical research networklaser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol,2009, 127: 1581-1583.
  • 7Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizimuab for agerelated macular degeneration. N Engl J Med, 2006,344: 1419-1431.
  • 8Moshfeghi AA,Rosenfeld PJ, Flynn HW Jr, et al. Endophthalmi-tis after intravitreal anti-vascular endothelial growth factor antago-nists ;a six-year experience at a university referral center. Retina,2011,31: 662-668.
  • 9McCannel CA. Meta-analysis of endophthalmitis after intra-vitrealinjection of antivascular endothelial growth factor agents : causativeorganisms and possible prevention strategies. Retina, 2011,31:654-661.
  • 10Moss JA, Sanislo SR, Ta CN. A prospective randomized evalua-tion of topical gatifloxacin on conjunctival flora in patients under-going intravitreal injections. Ophthalmology, 2009 , 116 : 1498-1501.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部